Alterations in sick dairy cows’ daily behavioural patterns

por Dittrich, I., Gertz, M., Krieter, J.
Publicado 2019

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

por Vu, T, Gonsalves, W, Kumar, S, Dispenzieri, A, Lacy, M Q, Buadi, F, Gertz, M A, Rajkumar, S V
Publicado 2015

Positron emission tomography-computed tomography in the diagnostic evaluation of smoldering multiple myeloma: identification of patients needing therapy

por Siontis, B, Kumar, S, Dispenzieri, A, Drake, M T, Lacy, M Q, Buadi, F, Dingli, D, Kapoor, P, Gonsalves, W, Gertz, M A, Rajkumar, S V
Publicado 2015

Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis

por Merlini, G, Lousada, I, Ando, Y, Dispenzieri, A, Gertz, M A, Grogan, M, Maurer, M S, Sanchorawala, V, Wechalekar, A, Palladini, G, Comenzo, R L
Publicado 2016

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Publicado 2018

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

por Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., Anderson, K. C.
Publicado 2019

MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts

por Hodge, L S, Elsawa, S F, Grote, D M, Price-Troska, T L, Asmann, Y W, Fonseca, R, Gertz, M A, Witzig, T E, Novak, A J, Ansell, S M
Publicado 2011

Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era

por Chakraborty, R, Muchtar, E, Kumar, S K, Jevremovic, D, Buadi, F K, Dingli, D, Dispenzieri, A, Hayman, S R, Hogan, W J, Kapoor, P, Lacy, M Q, Leung, N, Gertz, M A
Publicado 2016

Predicting Peripheral Blood Stem Cell Harvest Failure Using Circulating CD34 Levels: Developing Target-Based Cut-Points for Early Intervention

por Sinha, S, Gastineau, D, Micallef, I, Hogan, W, Ansell, S, Buadi, F, Dingli, D, Dispenzieri, A, Gertz, M, Greiner, C, Hayman, S, Inwards, D, Johnston, P, Lacy, M, Litzow, M, Porrata, L, Winters, JL., Kumar, S
Publicado 2010

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation

por Roy, V, Stewart, A K, Bergsagel, P L, Dispenzieri, A, Laumann, K, Allred, J, Lacy, M Q, Fonseca, R, Reeder, C B, Kumar, S, Rivera, C E, Gertz, M A, Buadi, F K, Hayman, S R, Rajkumar, S V
Publicado 2015

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma

por Ravi, P, Kumar, S, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R S, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2017

P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

por Gertz, M., Cohen, A., Comenzo, R., Kastritis, E., Landau, H., Libby, E., Liedtke, M., Sanchorawala, V., Schönland, S., Wechalekar, A., Ando, Y., Koh, Y., Zonder, J., Palladini, G., Nie, C., Karp, C., Jin, Y., Conrad, A., Kinney, G., Merlini, G.
Publicado 2023

Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma

por Gonsalves, W I, Leung, N, Rajkumar, S V, Dispenzieri, A, Lacy, M Q, Hayman, S R, Buadi, F K, Dingli, D, Kapoor, P, Go, R S, Lin, Y, Russell, S J, Lust, J A, Zeldenrust, S, Kyle, R A, Gertz, M A, Kumar, S K
Publicado 2015

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma

por Ansell, S M, Hodge, L S, Secreto, F J, Manske, M, Braggio, E, Price-Troska, T, Ziesmer, S, Li, Y, Johnson, S H, Hart, S N, Kocher, J-P A, Vasmatzis, G, Chanan-Kahn, A, Gertz, M, Fonseca, R, Dogan, A, Cerhan, J R, Novak, A J
Publicado 2014

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma

por Ravi, P, Kumar, S, Larsen, J T, Gonsalves, W, Buadi, F, Lacy, M Q, Go, R, Dispenzieri, A, Kapoor, P, Lust, J A, Dingli, D, Lin, Y, Russell, S J, Leung, N, Gertz, M A, Kyle, R A, Bergsagel, P L, Rajkumar, S V
Publicado 2016

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial...

por Brannagan, T. H., Wang, A. K., Coelho, T., Waddington Cruz, M., Polydefkis, M. J., Dyck, P. J., Plante‐Bordeneuve, V., Berk, J. L., Barroso, F., Merlini, G., Conceição, I., Hughes, S. G., Kwoh, J., Jung, S. W., Guthrie, S., Pollock, M., Benson, M. D., Gertz, M.
Publicado 2020

P1159: A MULTICENTER, INTERNATIONAL COLLABORATIVE STUDY EVALUATING FRONTLINE THERAPY WITH BENDAMUSTINE RITUXIMAB FOR WALDENSTRÖM MACROGLOBULINEMIA

por Zanwar, S., Abeykoon, J., Castillo, J., Durot, E., Kastritis, E., Uppal, E., Morel, P., Tawfiq, R., Montes, L., Paludo, J., Sarosiek, S., Kumar, S., Ogunbiyi, O., Cornillet-Lefebvre, P., Kyle, R., Delmer, A., Gertz, M., Dimopoulos, M., Ansell, S., Treon, S., D’Sa, S., Kapoor, P.
Publicado 2022

P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP

por Abdallah, N., Dispenzieri, A., Muchtar, E., Buadi, F., Kapoor, P., Lacy, M., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Leung, N., Dingli, D., Go, R., Lin, Y., Gonsalves, W., Binder, M., Kourelis, T., Warsame, R., Kyle, R., Rajkumar, S., Gertz, M., Kumar, S.
Publicado 2022

Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death

por Warsame, R, Kumar, S K, Gertz, M A, Lacy, M Q, Buadi, F K, Hayman, S R, Leung, N, Dingli, D, Lust, J A, Ketterling, R P, Lin, Y, Russell, S, Hwa, L, Kapoor, P, Go, R S, Zeldenrust, S R, Kyle, R A, Rajkumar, S V, Dispenzieri, A
Publicado 2015

P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE

por Vaxman, I., Kumar, S., buadi, F., Lacy, M., Dingli, D., Fonder, A., Hobbs, M., Hayman, S., hwa, L. Y., Kouralis, T., Warsame, R., Muchtar, E., Nelson, L., Kapoor, P., Grogan, M., Go, R., Gonsalves, W., Siddiqi, M., Robert, K., Rajkumar, V., Gertz, M., Dispenzieri, A.
Publicado 2022